Search

everythinglearnresearchcommunity

for

Search:↓

Effective management of children's hair loss involves accurate diagnosis, various treatments, and supportive care.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Bcl-2 overexpression protects against UVB damage but worsens hair loss from chemotherapy.

Vitiligo is not linked to coeliac disease, but a small number of alopecia areata patients may have it, suggesting they should be tested for coeliac disease.

Using patients' own fat-derived cells to treat alopecia areata significantly improved hair growth and was safe.

Combining diphenylcyclopropenone with anthralin is more effective for hair regrowth in alopecia areata than using diphenylcyclopropenone alone, but may cause more side effects.

Kids with alopecia areata may experience more stress but not necessarily feel more anxious or depressed than others.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.

DPCP helps treat severe hair loss, but 5% minoxidil doesn't add benefits.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Hair loss from mood stabilizers is common but can be managed without stopping the medication.

Some treatments like intralesional steroids and 5α-reductase inhibitors are effective for frontal fibrosing alopecia, but more research is needed.

Low dose oral minoxidil helps regrow hair in permanent chemotherapy-induced alopecia.

No treatments fully cure or prevent alopecia areata; some help but have side effects or need more research.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

Most dogs with alopecia had higher than normal levels of certain hormones, but hair loss might not always be linked to these hormone changes.

Alefacept showed some effectiveness for alopecia areata but needs more research.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

IGF-1 may affect hair growth and loss, but more research is needed to confirm effective and safe treatments.

Treatments for Frontal Fibrosing Alopecia have not been proven effective.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.

Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.

Some drugs used to treat inflammation may cause hair loss.